The Place of Sulfonylureas in Guidelines: Why Are There Differences?

Diabetes Ther. 2020 Jun;11(Suppl 1):5-14. doi: 10.1007/s13300-020-00811-3. Epub 2020 Apr 22.

Abstract

This review describes a presentation at a recent symposium entitled "SUs in the treatment of T2DM: a fresh look and new insights" on Wednesday September 18, 2019 at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. It examines the current role of sulfonylureas (SUs) in the management of type 2 diabetes mellitus (T2DM) and gives the author's personal perspective of how this therapeutic class has performed in both local and international guidelines. The place of SUs within current guidelines is highlighted, and a critical appraisal of the reasons for the differences between guidelines given. Finally, comparison of evidence-based guidelines and consensus reports is discussed.

Keywords: Consensus report; Evidence-based guidelines; Sulfonylureas; Type 2 diabetes mellitus.

Publication types

  • Review